-+ 0.00%
-+ 0.00%
-+ 0.00%

TG Therapeutics Q3 2026 net income drops 86% to $55.46 million

PUBT·11/09/2026 12:04:40
Listen to the news
TG Therapeutics Q3 2026 net income drops 86% to $55.46 million
  • TG Therapeutics’ third-quarter 2026 net income fell 86% to $55.46 million; the year-earlier quarter included a $365 million tax benefit.
  • Total revenue climbed 61% to $259.94 million, while BRIUMVI U.S. net product revenue rose approximately 52% to $232.6 million.
  • Topline Phase 3 results for subcutaneous BRIUMVI are expected at year-end 2026 or in the first quarter of 2027.
  • Full-year 2026 guidance increased to approximately $1 billion in total global revenue and $915–$920 million in BRIUMVI U.S. net product revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109560314) on November 09, 2026, and is solely responsible for the information contained therein.